Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions | |
pubmed:issue |
6
|
pubmed:dateCreated |
1992-6-19
|
pubmed:abstractText |
In a randomized, controlled trial of recombinant interferon alfa-2b with or without prednisone priming in Chinese adults with chronic hepatitis B virus infection, stratified randomization for pretreatment serum alanine aminotransferase levels was done. Partial or complete antiviral responses were achieved in 17 (21.5%) of 79 treated patients and 3 (8.3%) of 36 controls (P = 0.14). The response to interferon treatment was significantly better in those who had elevated pretreatment transaminase levels and comparable to that reported in white patients [15 (38.5%) of 39 patients compared with 2 (5%) of 40 who had normal pretreatment transaminase levels (P = 0.0005)]. The spontaneous seroconversion rate was also higher among the controls with elevated transaminase levels [3 (18.8%) of 16 compared with 0 of 20 with normal transaminase levels], but this difference was not statistically significant (P = 0.16). Among the interferon-treated patients, prednisone priming appeared to have a marginal benefit over treatment with interferon alone in patients with elevated transaminase levels (43% vs. 33%), but not in those with normal transaminase levels (0% vs. 9.5%). It was confirmed that Chinese patients with normal transaminase levels respond very poorly to interferon alfa therapy. However, the response was significantly better in patients with elevated transaminase levels.
|
pubmed:language |
eng
|
pubmed:journal | |
pubmed:citationSubset |
AIM
|
pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/Alanine Transaminase,
http://linkedlifedata.com/resource/pubmed/chemical/Interferon-alpha,
http://linkedlifedata.com/resource/pubmed/chemical/Prednisone,
http://linkedlifedata.com/resource/pubmed/chemical/Recombinant Proteins,
http://linkedlifedata.com/resource/pubmed/chemical/interferon alfa-2b
|
pubmed:status |
MEDLINE
|
pubmed:month |
Jun
|
pubmed:issn |
0016-5085
|
pubmed:author | |
pubmed:issnType |
Print
|
pubmed:volume |
102
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
2091-7
|
pubmed:dateRevised |
2011-11-17
|
pubmed:meshHeading |
pubmed-meshheading:1587429-Adult,
pubmed-meshheading:1587429-Alanine Transaminase,
pubmed-meshheading:1587429-Chronic Disease,
pubmed-meshheading:1587429-Drug Therapy, Combination,
pubmed-meshheading:1587429-Female,
pubmed-meshheading:1587429-Hepatitis B,
pubmed-meshheading:1587429-Humans,
pubmed-meshheading:1587429-Interferon-alpha,
pubmed-meshheading:1587429-Liver,
pubmed-meshheading:1587429-Male,
pubmed-meshheading:1587429-Middle Aged,
pubmed-meshheading:1587429-Prednisone,
pubmed-meshheading:1587429-Recombinant Proteins
|
pubmed:year |
1992
|
pubmed:articleTitle |
A controlled trial of interferon with or without prednisone priming for chronic hepatitis B.
|
pubmed:affiliation |
Department of Medicine, University of Hong Kong.
|
pubmed:publicationType |
Journal Article,
Clinical Trial,
Randomized Controlled Trial,
Research Support, Non-U.S. Gov't
|